Continued Use of Blarcamesine May Slow Cognitive Decline in Alzheimer Disease: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on new data from a phase 2b/3 clinical trial designed to assess the safety and tolerability and long-term efficacy of blarcamesine on cognition and function in individuals with early Alzheimer disease (AD).

The study

The ATTENTION-AD trial followed a 48-week double-blind clinical trial with an open-label extension (OLE) phase lasting up to 144 weeks. Participants in North America and Europe underwent OLE treatment for 96 weeks, while those in Australia were treated for up to 144 weeks.

The findings

Cognitive benefits. Using the Alzheimer’s Disease Assessment Scale-Cognitive Subcale-13 (ADAS-Cog13) a measure of cognitive function, early-start patients showed a clinically meaningful improvement at week 144 (LS mean difference: -2.70; P =.035), with an even greater difference that reached statistical significance observed at week 192 (LS mean difference: -3.83; P =.016).

Functional benefits. Findings from delayed-start analysis on the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Scale, a measure of daily living function, also favored early- vs delayed-start participants with the cohort showing a numerical improvement at week 144 (LS mean difference: +2.32; P =.125).

Click here for more details.